Literature DB >> 7897262

Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1.

S Okitsu-Negishi1, S Furusawa, Y Kawa, S Hashira, S Ito, F Hiruma, M Mizoguchi, K Yoshino, T Abe.   

Abstract

In order to study the effect of human immunoglobulin preparations for intravenous use (IVIg) on the production and activity of interleukin-1 (IL-1) derived from monocytes, we treated cultured monocytes with IVIg and examined the lymphocyte-activating factor (LAF) activity of IL-1 in the culture supernatants. The results showed that IVIg suppressed the activity from most healthy adults and some febrile children with acute respiratory disease or Kawasaki disease. Further studies revealed that intact Ig (whole molecular Ig) did not suppress the mRNA expression of IL-1 alpha or IL-1 beta in mononuclear cells, that intact Ig and pepsin-digested Ig inhibited the LAF activity of recombinant IL-1 (rIL-1) and also that intact Ig contains immunoglobulin (probably anti-IL-1 antibody) which binds with rIL-1 by dot blotting using biotin-streptavidin. These results suggest that IVIg suppresses neither IL-1 synthesis nor the release of IL-1 from monocytes but does neutralize IL-1 alpha and IL-1 beta activity by binding IL-1 proteins as an anti-IL-1 antibody.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7897262     DOI: 10.1007/bf02918224

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  10 in total

1.  Induction of IL-1 secretion from human monocytes by Fc region subfragments of human IgG1.

Authors:  E L Morgan; M V Hobbs; D J Noonan; W O Weigle
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

2.  Regulation of interleukin 1 gene expression by adherence and lipopolysaccharide.

Authors:  R C Fuhlbrigge; D D Chaplin; J M Kiely; E R Unanue
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

3.  Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation.

Authors:  L J Rosenwasser; C A Dinarello
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

4.  Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples.

Authors:  B A White; F C Bancroft
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

5.  Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes.

Authors:  N Kumagai; S H Benedict; G B Mills; E W Gelfand
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

6.  There is more than one interleukin 1.

Authors:  J J Oppenheim; E J Kovacs; K Matsushima; S K Durum
Journal:  Immunol Today       Date:  1986-02

7.  Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells.

Authors:  S J Warner; K R Auger; P Libby
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

8.  Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.

Authors:  C A Dinarello; T Ikejima; S J Warner; S F Orencole; G Lonnemann; J G Cannon; P Libby
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

9.  Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits.

Authors:  M Iwata; T Shimozato; H Tokiwa; E Tsubura
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

10.  Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells.

Authors:  S J Warner; K R Auger; P Libby
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

  10 in total
  4 in total

1.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

2.  Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Authors:  Youngho Lee; Danica J Schulte; Kenichi Shimada; Shuang Chen; Timothy R Crother; Norika Chiba; Michael C Fishbein; Thomas J A Lehman; Moshe Arditi
Journal:  Circulation       Date:  2012-02-23       Impact factor: 29.690

3.  Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Authors:  M Gupta; G J Noel; M Schaefer; D Friedman; J Bussel; R Johann-Liang
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

Review 4.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.